Figure 1.

Ikaros deficiency in host APCs does not increase GVL responses regardless of enhanced GVHD in experimental HCT. WT B6 Ly5.2 animals were lethally irradiated with 11 Gy and infused with 5 × 10⁶ bone marrow (BM) cells and 5 × 10⁶ splenocytes from syngeneic Ly5.1 WT B6 or Ik^−/− B6 donors. Four months later these [B6→B6Ly5.2] or [Ik^−/−→B6Ly5.2] chimeras received 9 Gy irradiation and 1 × 10⁶ CD90⁺ T cells together with 5 × 10⁶ BM cells from either syngeneic B6 or allogeneic MHC-matched or multiple miHA-mismatched C3H.sw donors concurrently with syngeneic MBL-2 tumor at the same time as allo-HCT. (A) Overall survival data of GVHD study. (•) B6→[B6→B6Ly5.2], (▴) B6→[Ik^−/−→B6Ly5.2], (Ë) C3H.sw→[B6→B6Ly5.2], (–)C3H.sw→[Ik^−/−→B6Ly5.2]. Data shown are one representative dataset (n=3–5/each group) of 5 independent experiments. (B, C) Tumor mortality data for MBL-2 at 10,000 cells/mouse (n=10–18/group) (B) and 5,000 cells/mouse (n=4–10/group). (C) (•) B6→[B6→B6Ly5.2], (▴) B6→[Ik^−/−→B6Ly5.2], (Ë) C3H.sw→[B6→B6Ly5.2], (–)C3H.sw→[Ik^−/−→B6Ly5.2]. Data are combined from 2 or 3 independent experiments. (D) Tumor growth was monitored using bioluminescence imaging (BLI) after allo-HCT (n=2–5). Representative data from 3 independent experiments are shown. (E) Tumor mortality data of the same model using a different syngeneic tumor, EL-4 (10,000 cells/mouse, n=3–12/group). (•) B6→[B6→B6Ly5.2], (Ë) C3H.sw→[B6→B6Ly5.2], (–) C3H.sw→[Ik^−/−→B6Ly5.2]. Data are combined from 2 independent experiments.